A new pathway of tumor promotion by the okadaic acid class compounds.
Fujiki
H
H
Cancer Prevention Division, National Cancer Center Research Institute, Tokyo, Japan.
Suganuma
M
M
Nishiwaki
S
S
Yoshizawa
S
S
Winyar
B
B
Sugimura
T
T
Schmitz
F J
FJ
D000818:Animals; D001667:Binding, Competitive; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002273:Carcinogens / Q000145:classification / Q000378:metabolism / Q000494:pharmacology*; D003600:Cytosol / Q000378:metabolism; D004273:DNA, Neoplasm / Q000235:genetics; D004988:Ethers, Cyclic / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008387:Marine Toxins; D051379:Mice; D015394:Molecular Structure; D009154:Mutation; D009687:Nuclear Proteins / Q000378:metabolism; D019319:Okadaic Acid / Q000031:analogs & derivatives; D010080:Oxazoles / Q000378:metabolism / Q000494:pharmacology; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors; D010750:Phosphoproteins / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism; D011506:Proteins / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics; D011714:Pyrans / Q000494:pharmacology; D016601:RNA-Binding Proteins; D011955:Receptors, Drug; D012867:Skin / Q000187:drug effects / Q000378:metabolism; D012878:Skin Neoplasms / Q000139:chemically induced / Q000235:genetics; D013141:Spiro Compounds / Q000378:metabolism / Q000494:pharmacology; D013329:Structure-Activity Relationship; D000097796:Nucleolin
D002273:Carcinogens; D004273:DNA, Neoplasm; D004988:Ethers, Cyclic; D008387:Marine Toxins; D009687:Nuclear Proteins; D019319:Okadaic Acid; D010080:Oxazoles; D010749:Phosphoprotein Phosphatases; D010750:Phosphoproteins; D011494:Protein Kinases; D011506:Proteins; D016283:Proto-Oncogene Proteins p21(ras); D011714:Pyrans; D016601:RNA-Binding Proteins; D011955:Receptors, Drug; D013141:Spiro Compounds; D000097796:Nucleolin; C065561:okadaic acid receptor; C051904:dinophysistoxin 1; C065560:acanthifolicin; C059041:calyculin A; C501009:HRAS protein, human